The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.
INTRODUCTION
Interferon regulatory factor-8 (IRF8) (also called interferon consensus sequence binding protein, ICSBP) is an interferon γ-inducible transcription factor, expressed during hematopoiesis in cells of the myeloid, as well as of the B-lymphocyte lineage [1, 2] . In normal hematopoiesis, IRF8 expression is high in myeloid, lymphoid and dendritic progenitors [3] . On the other hand, levels of IRF8 are low or absent in leukemic blasts from a majority of chronic myeloid leukemia (CML) or acute myeloid leukemia (AML) patients [4] , often due to promoter methylation [5, 6] , suggesting an anti-leukemic role for IRF8. Several mechanisms downstream of IRF8 that are relevant for an anti-oncogenic function have been reported, including repression of BCL2L1 (Bcl-X L ) [7] , MYC [8] , BCL2 [9] , PTPN13 [10] , CTNNB1 (β-catenin) [11, 12] , and enhanced expression of CASP3 [7] , and NF1 [13] . Loss of IRF8 in mice leads to deregulated myeloid differentiation with an accumulation of neutrophil-like cells, resembling human CML [14] . CML is driven by the oncogenic fusion protein BCR-ABL with constitutive tyrosine kinase activity [15] . Forced expression of IRF8 antagonizes the BCR-ABL-induced leukemic phenotype in vitro and in vivo [8, 9] .
Moreover, treatment of leukemic cells with the BCR-ABL-inhibitor imatinib or with retinoic acid, both clinically used in the treatment of leukemia, increases expression of IRF8 [16, 17] , further emphasizing the tumor suppressor function of IRF8 in myeloid malignancies.
Transcriptional control of IRF8 in leukemic cells is incompletely understood. The
Wilm's tumor gene 1 (WT1) protein is a zinc-finger transcription factor normally expressed in a small subset of hematopoietic progenitor cells [18, 19, 20, 21, 22] , suggesting a role in early hematopoiesis. WT1 is commonly overexpressed in myeloid leukemias [21, 23, 24, 25, 26] and WT1 cooperates with the leukemia fusion protein RUNX1 (AML1-ETO) to rapidly induce leukemia in mice, demonstrating a leukemogenic role for WT1 [27] . Recently, we showed that WT1 targets the IRF8-promoter, resulting in transcriptional repression [16] . Moreover, expression levels of WT1 and IRF8 in primary acute myeloid leukemias are highly anticorrelated [16] .
Thus, WT1-mediated repression of IRF8 provides one explanation for the generally low expression of IRF8 in CML and AML. Interestingly, the constitutive tyrosine kinase activity of BCR-ABL causes increased expression of WT1, indicating a BCR-ABL-WT1-IRF8 pathway in CML [16, 28] .
The zinc-finger protein ZNF224 was first identified as a repressor of the human aldolase A gene [29] . In contrast to the restricted expression of WT1 in adult tissues, ZNF224 is ubiquitously expressed. A functional interaction between ZNF224 and WT1 was shown as ZNF224 functions as a coactivator of WT1 on the promoter of the vitamin D-receptor (VDR), demonstrating that ZNF224 can also activate transcription [30] . The role of ZNF224 in WT1-mediated transcriptional regulation was recently extended to a number of WT1-target genes involved in the regulation of apoptosis. On the promoter of these genes, ZNF224 acts as a co-activator of proapoptotic genes, while repressing expression of antiapoptotic WT1 target genes [31] . In this way, ZNF224 shifts the balance of antiapoptotic and proapoptotic signals in favor of the latter. Consistent with a proapoptotic role, overexpression of ZNF224 in leukemic cells potentiated the cytotoxic response to the cytostatic drug and antimetabolite cytarabine [31] , while WT1 can confer resistance to this treatment [32] .
Cytarabine is one of the most commonly used drugs used for treatment of AML [33] .
Within the cell, the pyrimidine nucleoside analog cytarabine is activated into ara-CTP which is incorporated into DNA of proliferating cells in place of deoxycytidine triphosphate (dCTP), thus blocking DNA synthesis, resulting in proliferation arrest and cell death [34] . Cytarabine may also be incorporated into DNA repair patches of quiescent cells, leading to inhibition of DNA-repair [35, 36] .
The aim of this work was to elucidate whether expression of the tumor suppressor IRF8 is affected by cytarabine, and whether ZNF224 cooperates with WT1 in transcriptional regulation of the IRF8-promoter.
MATERIAL AND METHODS:

Cell culture
The human kidney cancer cell line HEK293T/17 was cultured in Dulbecco's modified Eagle's medium, (Hyclone Laboratories Inc, Utah, U.S.A), supplemented with 10% fetal calf serum and 100 µg/ml streptomycin-penicillin mix (Bio-Whittaker Inc, MD, USA) at 37ºC in 5% CO2. The leukemic cell line K562 (DSMZ, Braunschweig, Germany) was cultured in RPMI 1640 (Gibco Life Technologies, NY, USA) supplemented with 10% fetal calf serum at 37ºC in 5% CO2. K562 cells were treated 1 µM cytarabine (Pfizer AB, Sollentuna, Sweden) for 72 h. Concentration of cytarabine was carefully titrated in initial experiments to generate maximal proliferation arrest.
Immunoblotting
Harvested cells for immunoblotting were resuspended in Laemmli buffer (#161-0737, Bio-Rad Laboratories, Hercules, CA, USA) containing 0.2M β-mercaptoethanol (Sigma-Aldrich). Proteins were separated by SDS-PAGE (12% TGX gel, #456-1043, Bio-Rad) and transferred to a Hybond ECL membrane (GE Healthcare, Uppsala, Sweden). Primary antibodies used were: rabbit anti-IRF8 antibody (MBS224027, MyBioSource.com, CA, USA), rabbit anti-ZNF224 (T3) antibody (29) , rabbit anti-WT1 (C-19, Santa Cruz, CA, USA), and mouse anti-GAPDH (7-B, Santa Cruz, CA, USA). The EZ-ECL kit (Biological Industries, Kibbutz Beit Haemek, Israel) was used for analysis of protein bands with a ChemiDoc TM XRS + system (BioRad).
shRNA-mediated knockdown of ZNF224
Pools of K562 cells expressing ZNF224 shRNA, were obtained as previously described [31] . Briefly, K562 cells were transfected with 1.5 µg of short-interfering RNA plasmid SH2351C3 (Open Biosystem, Huntsville, AL, USA) using the HiPerFect Reagent (Qiagen, Venlo, Netherlands), according to the manufacturer's protocol; transfection of a non-silencing shRNA (scrambled shRNA) (Open Biosystem) was used as negative control. Transfected cells were selected by culture in the presence of puromycin (500 µg/ml) (Promega Corporation, Wisconsin, USA) for 4
weeks. Suppression of ZNF224 protein expression in response to shRNA expression was previously characterized by immunoblotting [31] .
RNA isolation, reverse transcription and quantitative PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions, after which RNA was reverse transcribed using HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems Inc., Foster City, CA, USA) with random hexamer primers according to the manufacturer's instructions.
Quantitative PCR (qPCR) was carried out using TaqMan probe-based chemistry (Applied Biosystems); the probe for ZNF224 (Hs00273760_m1), IRF8
(Hs00175238_m1), WT1 (Hs00240913_m1), and the endogenous controls beta-actin (Hs99999903_m1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Hs99999905_m1) were purchased as Assay-on-Demand (Applied Biosystems). The amplification reactions were all performed in triplicates in a StepOnePlus (Applied Biosystems). Data were collected and analyzed using the Applied Biosystems
StepOne TM Real-Time PCR Software v2.0. The relative quantification in gene expression was determined using the ΔΔCt method [37] . Efficacy of the PCR amplification of controls and test was identical; parallelism of standard curves of the control and test was confirmed.
Transient transfection and luciferase-reporter assays
HEK293T/17 cells were transiently transfected using Lipofectamine reagent (Life Technologies, CA, USA) in 12-well plates with 200 ng of a luciferase reporter plasmid containing the proximal IRF8 promoter including a WT1 response element [16] , and the 3XFLAG-CMV-7.1-ZNF224 and pcDNA3WT1(+/-) expression plasmids at indicated combinations and concentrations. To normalize the luciferase assay a pRL-CMV plasmid (20 ng) encoding the renilla luciferase was used. Dual-Luciferase
Reporter Assay System (Promega Corporation, WI, USA) was performed 48h after the transfection, according to the manufacturer's instructions.
Chromatin Immunoprecipitation (ChIP) assay
ChIP experiments were performed using Chromatin Immunoprecipitation assay kit (Millipore, Darmstadt, Germany) according to the manufacturer's protocol. Briefly, cross-linked chromatin was prepared from HEK293T/17 cells transfected with 3XFLAG-CMV-7.1-ZNF224 or with pcDNA3WT1(+/-), or co-transfected with 3XFLAG-CMV-7.1-ZNF224 and pcDNA3WT1(+/-). The antibodies anti-ZNF224 (G-16), anti-WT1 (C19), and anti-HA were from Santa Cruz Biotechnology, TX, USA.
ChIP samples were analyzed by qPCR as described (Montano 2013 ), using 2 µl of immunoprecipitated material and 1 µl of input control diluted 1:30 as templates.
Specific primers for a WT1-binding region at -52 to -38 on IRF8 promoter were 5′-ttctcggaaagcagagcacttc-3′ (forward), and 5′-gccttaaaaagggtcgtggg-3'(reverse) (16) ; for a WT1-binding region at the aldolase A promoter 5'-ccctctgttccactgggcaagt-3'
(forward) and 5'-ccattccagttcccaggcctgggtg-3' (reverse) (31) ; and for the GAPDH promoter (used as negative control) 5′-ggtcgtattgggcgcctggtcacca-3′ (forward) and 5′-cacacccatgacgaacatgggggc-3′ [31] .
Co-immunoprecipitation assay
HEK293 cells were transfected with the plasmids p3XFLAG-ZNF224 and pcDNA3-WT1(+/-). Total protein extract, nuclear and cytoplasmic extracts were obtained as previously described [30] . Immunoprecipitation using an anti-WT1 antibody (F6 Santa
Cruz Biotechnology) or the IgG control antibody (Santa Cruz Biotechnology) was performed as described [30] .
Statistical analysis:
Statistical analysis was performed using the paired one-tailed t-test. Stars represent conventional significance levels; single star indicates, p<0.05, double stars p<0.01, and triple stars p<0.001.
RESULTS
Induction of IRF8 by cytarabine is correlated to upregulation of ZNF224.
Clinical intermediate doses of cytarabine produce plasma levels of 7 µM or higher [38] . We have previously shown that treatment of leukemic K562 cells with 1 µM cytarabine for 72 hours induces some degree of apoptosis, correlated to induction of ZNF224 [31] . Given the anti-oncogenic function of IRF8, we now asked whether this cytostatic drug also affects the levels of IRF8. As shown in Fig 1, treatment of K562 cells with cytarabine indeed upregulated the amount of IRF8 protein. The increase of IRF8 protein was correlated to strongly raised levels of IRF8 mRNA in K562 cells (Fig 2A) , indicating transcriptional effects. Confirming previous data [31] , cytarabine induced an upregulation also of ZNF224 (Fig 2B) . Cytarabine caused a prompt proliferation arrest ( Fig 2C) and significant cell death ( Fig 2D) . We conclude that cytarabine-induced IRF8 expression is correlated to upregulation of ZNF224.
Cytarabine-induced upregulation of IRF8 is dependent on levels of ZNF224
Given that ZNF224 can act as a cofactor to WT1 [30, 31] expression, as compared to control cells (Fig 3A) . Interestingly, the reduction in ZNF224 resulted in a corresponding decrease also of IRF8 levels, suggesting that ZNF224 influences the expression of IRF8 (Fig 3B) . After treatment with cytarabine, the induced increase of ZNF224, as well as the strongly induced increase of IRF8, was significantly quenched by shZNF224 (Fig 3A, B) , further supporting a role of ZNF224 in IRF8 expression. While suppression of ZNF224 on its own did not affect viability, as compared to control cells, cell death caused by cytarabine was dampened by expression of shZNF224 (Fig 3C) , consistent with previous data [31] . We conclude that knockdown of ZNF224 results in increased resistance to cytarabine, correlated to quenched upregulation of IRF8.
WT1-mediated repression of the IRF8-promoter is counteracted by ZNF224
IRF8 has been defined as a target gene repressed by WT1 [16] . Our findings above, suggesting that ZNF224 positively affects IRF8-expression, therefore led us to hypothesize that ZNF224 acts as a cofactor of WT1 on the IRF8 promoter. To investigate direct effects of ZNF224 on the transcriptional regulation of the IRF8
promoter, we performed luciferase-reporter experiment in HEK293 cells. IRF8
expression is suppressed by WT1, in particular by the WT1(+/-) isoform, in leukemic cells [16] . The WT1(+/-) isoform represses transcription from an IRF8 promoter construct containing 970 bp upstream of the transcription start [16] . When this promoter was transfected to HEK293 cells, ZNF224 alone did not affect promoter activity, while, as expected, WT1(+/-) by itself resulted in suppression of the IRF8 promoter (Fig 4) . Interestingly, increasing amounts of ZNF224 showed a doseresponse alleviation of the WT1-mediated suppression, indicating that ZNF224
interferes with WT1-mediated transcriptional repression of the IRF8 promoter (Fig 4) .
WT1(+/-) interacts with ZNF224 in the nucleus
The findings above raised the question whether ZNF224 interacts with WT1(+/-). We performed coprecipitation experiments to investigate that issue. Since there are no isoform-specific antibodies to WT1 available, we used HEK293 cells that lack detectable expression of endogenous WT1. The cells were transfected with ZNF224
and WT1(+/-) after which nuclear and cytosolic subcellular fractions were prepared.
As shown in Fig 5A, immunoprecipitation of WT1(+/-) coprecipitated ZNF224 in the nuclear fraction, but not in the cytosol (Fig 5B) . Nuclear, but not cytosolic, interaction is in agreement with previous data concerning the interaction between ZNF224 and the WT1(-/-) splice variant [30] . Analysis of c-myc and tubulin was used as markers for the nucleus and cytosol, respectively (Fig 5C and 5D) . We conclude that ZNF224 binds to WT1(+/-) in the nucleus, consistent with a role for ZNF224 in modulation of WT1-mediated transcriptional control.
WT1(+/-) recruits ZNF224 to the IRF8 promoter.
To find further evidence for interaction between WT1(+/-) and ZNF224 on the IRF8
promoter, we performed chromatin immunoprecipitation (ChIP) experiments. Again, HEK293 cells lacking endogenous WT1 expression were utilized. After transfection of cells with WT1(+/-), ZNF224, or with both, ChIP was performed with antibodies against WT1 or ZNF224. Precipitation with antibody against hemagglutinin (HA) and PCR-amplification of GAPDH were used as negative controls. As shown in Fig 6A, WT1 showed binding to the IRF8 promoter when transfected alone, as previously reported [16] . Also in consistence with previous data, ZNF224 alone did bind to the aldolase A promoter [29] (Fig 6B) . However, ZNF224 alone failed to bind to the IRF8 promoter ( Fig 6B) . Interestingly, upon cotransfection with both ZNF224 and WT1(+/-), the ChIP analysis showed binding of ZNF224 to the IRF8 promoter ( Fig   6C) . These results demonstrate that ZNF224 is dependent on WT1 for this particular binding and thus that WT1 recruits ZNF224 to the IRF8 promoter. As control, Fig 6D shows immunoblot analysis of ZNF224 and WT1 protein in transfected cells from which the ChIP analyses were performed. We conclude that ZNF224 is recruited to the IRF8 promoter in a WT1-dependent manner.
DISCUSSION
Preclinical and clinical data emphasize the anti-oncogenic role for the transcription factor IRF8 in hematopoietic malignancies. In consistence with a tumor suppressor function, expression of IRF8 is commonly downregulated or absent in myeloid leukemias [4, 5, 6] . Certain oncogenes, such as the fusion protein BCR-ABL, signal for downmodulation of IRF8-expression [39] , with the transcription factors WT1 and STAT5 as downstream mediators, targeting and repressing the IRF8-promoter [16, 28, 40] . In this study, we show that IRF8 is transcriptionally upregulated by the cytostatic drug cytarabine involving mechanisms that include the zinc finger-protein ZNF224, which binds to and counteracts the repressive effect of WT1 on the IRF8-promoter.
The conclusion that IRF8 is transcriptionally upregulated in response to cytarabine is specifically binds to DNA on the promoter of the aldolase A gene [29] , but can also indirectly bind to certain promoters via interaction with the transcription factor WT1 [30] , thus fine tuning the effect of WT1 on transcription [31] . Here, we show that ZNF224 is recruited to the IRF8 promoter via binding to WT1, as demonstrated by co-precipitation and ChIP-experiments. Our finding that the WT1+/-isoform interacts with ZNF224 in the nucleus is in accordance with previous data for the WT1-/-isoform [30] , indicating that the 17AA insert in the WT+/-isoform is dispensable for binding to ZNF224. Importantly, our ChIP experiments clearly show the functional relevance of the interaction between WT1+/-and ZNF224, since the latter is not able to bind to the IRF8 promoter, unless WT1+/-is also present. The ChIP analysis demonstrates recruitment of ZNF224 to the IRF8 promoter in the absence of cytarabine treatment. Whether cytarabine signaling results in protein modifications of WT1 or ZNF224 that increase their interaction, or if the effect of cytarabine is merely a result of increased levels of ZNF224 (Fig 2 and 3) and decreased expression of WT1
[31], remains to be defined.
The notion that ZNF224 is dependent on WT1 to be active on the IRF8 promoter is further supported by our results showing that ZNF224 has no effect on its own on the These data extend our previous findings that ZNF224 can act as a transcriptional cofactor of WT1 [30, 31] . Here, we demonstrate that ZNF224 is able to counteract the repressive effect of oncogenic WT1 on the tumor suppressor IRF8, providing novel insights into the regulative mechanisms triggered by the WT1/ZNF224 complex in leukemic cells.
CONCLUSIONS:
This work shows that the myeloid tumor suppressor IRF8 is induced in leukemic cells by the commonly used cytostatic drug cytarabine. This effect of cytarabine is dependent on ZNF224, which modulate transcription of IRF8 by binding to WT1 on the promoter, thus counteracting the repressive effect of the oncoprotein WT1 on IRF8 expression. We conclude that WT1 and ZNF224 are regulators of the tumor suppressor IRF8 in the response to cytarabine. WT1(+/-) (A), or ZNF224 (B), or both ZNF224 and WT1 (C), were transfected to 293HEK cells after which chromatin immunoprecipitation (ChIP) using an antibody against ZNF224 (G16, Santa Cruz) or against WT1 (C19, Santa Cruz) was performed.
ChIP with anti-HA antibody was used as negative control. Following ChIP, PCR with primers specific for the IRF8-promoter with a WT1 response element was performed as described in Methods. Primers specific for the aldolaseA and GAPDH promoter were used as positive and negative controls, respectively. As control of transfected proteins, ZNF224 and WT1 protein in cell lysates were analyzed by immunoblotting (D).
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